RecruitingNCT06301945

Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors

Artificial Intelligence for Histopathological Classification and Recurrence Prediction of Thymic Epithelial Tumors


Sponsor

Erasmus Medical Center

Enrollment

1,020 participants

Start Date

Aug 1, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Thymic epithelial tumors are rare neoplasms in the anterior mediastinum. The cornerstone of the treatment is surgical resection. Administration of postoperative radiotherapy is usually indicated in patients with more extensive local disease, incomplete resection and/or more aggressive subtypes, defined by the WHO histopathological classification. In this classification thymoma types A, AB, B1, B2, B3, and thymic carcinoma are distinguished. Studies have shown large discordances between pathologists in subtyping these tumors. Moreover, the WHO classification alone does not accurately predict the risk of recurrence, as within subtypes patients have divergent prognoses. The investigators will develop AI models using digital pathology and relevant clinical variables to improve the accuracy of histopathological classification of thymic epithelial tumors, and to better predict the risk of recurrence. In this multicentric and international project three existing databases will be used from Rotterdam, Maastricht and Lyon. For all models one database will be used to build AI models, and the other two for external validation. The ultimate goal of this project is to develop AI models that support the pathologist in correctly subtyping thymic epithelial tumors, in order to prevent patients from under- or overtreatment with adjuvant radiotherapy.


Eligibility

Plain Language Summary

Simplified for easier understanding

This study develops and validates an artificial intelligence (AI) model to help pathologists diagnose and predict outcomes for people with thymic tumors — rare cancers that start in the thymus gland in the chest. The AI is trained to recognize tumor subtypes and predict whether the cancer is likely to come back. **You may be eligible if...** - You have a diagnosis of thymoma (any subtype: A, AB, B1, B2, or B3) or thymic carcinoma - Your diagnosis was one where pathologists had some disagreement (less than 70% agreement during the model training phase) - For the validation phase: you have a documented outcome of whether the cancer recurred within 5 years **You may NOT be eligible if...** - You have a thymic tumor other than those listed above - Required pathology or outcome data are not available Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTArtificial Intelligence Diagnostics

AI Diagnostics uses advanced algorithms for precise histological image analysis to help diagnose disease, including subtype.

DIAGNOSTIC_TESTRecurrence Prediction Tool

This AI tool evaluates thymic tumour data and other clinical data and calculates the risk of recurrence, with the aim of analysing whether there is an association with specific subtypes of thymic epithelial tumours and clinical data.


Locations(1)

Erasmus MC

Rotterdam, South Holland, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06301945


Related Trials